retatrutide clinical trial phase Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide Availability & Timeline |

A physician who knows your baseline can tell you exactly what would change the answer

Probiotic GLP-1 supplements as finished products have not been studied in published randomized controlled trials comparable to pharmaceutical research

This approach reduces the long-term side effect burden and cost of peptide therapy

Resistance training two to three times per week, combined with adequate protein intake, sends muscle-building signals that counteract the catabolic effects of caloric restriction

To view or add a comment, sign in Diabetic neuropathy is a leading cause of foot complications, including ulcers and amputations, yet early detection and new interventions can make all the difference

Eli Lilly spent years optimizing the triple agonist design through peptide research and clinical studies